Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Short-term Investments (2025)

Neuphoria Therapeutics (NEUP) has disclosed Short-term Investments for 1 consecutive years, with $79647.0 as the latest value for Q4 2025.

  • Quarterly Short-term Investments changed N/A to $79647.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $79647.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $77945.0 for FY2025, N/A changed from the prior year.
  • Short-term Investments for Q4 2025 was $79647.0 at Neuphoria Therapeutics, up from $78564.0 in the prior quarter.
  • The five-year high for Short-term Investments was $79647.0 in Q4 2025, with the low at $77945.0 in Q2 2025.